Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
▼
$0.00
$3K1.059,214 shsN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
$0.00
$0.00
$0.00
▼
$0.03
$3K-0.076,414 shs1,000 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$3K1.3116,456 shs851 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.00
$0.01
$0.00
▼
$1.50
$1K-0.44710 shs43 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%-50.00%
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
0.00%+100.00%+100.00%+100.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%-75.00%0.00%-50.00%-90.91%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%-90.99%-90.99%-90.99%-99.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
▼
$0.00
$3K1.059,214 shsN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
$0.00
$0.00
$0.00
▼
$0.03
$3K-0.076,414 shs1,000 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$3K1.3116,456 shs851 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.00
$0.01
$0.00
▼
$1.50
$1K-0.44710 shs43 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%-50.00%
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
0.00%+100.00%+100.00%+100.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%-75.00%0.00%-50.00%-90.91%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%-90.99%-90.99%-90.99%-99.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.00N/AN/AN/ANaN
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
N/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.01N/AN/A$0.79 per share0.00
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.00N/AN/A($11.07) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18M-$0.18N/AN/AN/AN/AN/AN/AN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%8/11/2026 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
5.50%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
Statera Biopharma, Inc. stock logo
STAB
Statera Biopharma
2013.34 millionN/ANot Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000No Data

Recent News About These Companies

Trevena Inc.
May 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/TRVN/financials
Trevena Restructures China Royalty Rights to Exit Debt
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-restructures-china-royalty-rights-to-exit-debt?utm_source=marketbeat.com&utm_medium=referral
Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored
July 8, 2025  |  msn.comhttps://www.msn.com/en-us/sports/mlb/softball-conrad-weiser-s-alex-trevena-earns-statewide-player-of-the-year-award-5-other-berks-players-honored/ar-AA1IcIZz
Trevena, Inc. (TRVN) - Yahoo Finance
June 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TRVN/press-releases/
Trevena Enters Securities Exchange Agreement with Investor
May 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-enters-securities-exchange-agreement-with-investor?utm_source=marketbeat.com&utm_medium=referral
Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win
April 11, 2025  |  readingeagle.comR
Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater
March 9, 2025  |  msn.comhttps://www.msn.com/en-us/music/news/vanessa-hudgens-and-oliver-trevena-appear-at-expo-west-for-caliwater/ar-AA1Axb5h
JMP Securities downgrades Trevena (TRVN) to a Hold
December 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jmp-securities-downgrades-trevena-trvn-to-a-hold-1034177267
‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment
December 16, 2024  |  yahoo.comhttps://www.yahoo.com/entertainment/plane-actor-oliver-trevena-signs-153000870.html
Lyme Regis town councillor John Trevena stand down
December 11, 2024  |  bridportnews.co.ukB
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
December 10, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2381592/trevena-trvn-could-find-a-support-soon-here-s-why-you-should-buy-the-stock-now?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2381592
Trevena appoints new financial chief
November 29, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/trevena-appoints-new-financial-chief-93CH-3745129
Trevena Appoints Katrine Sutton as New CFO
November 27, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-appoints-katrine-sutton-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
HC Wainwright & Co. Downgrades Trevena (TRVN)
November 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-trevena-trvn/ar-AA1u9FYi
Trevena, Inc. Navigates Financial Challenges and Strategic Changes
November 9, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/trevena-inc-navigates-financial-challenges-and-strategic-changes/ar-AA1tMJqv
Chester County biopharm firm's latest layoffs impact its C-suite
November 7, 2024  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2024/11/07/trevena-chesterbrook-layoffs-c-suite-pain-medicine.html
Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review
November 7, 2024  |  fiercebiotech.comF
Trevena Reports Third Quarter 2024 Results and Provides Business Update
November 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/07/2976530/0/en/trevena-reports-third-quarter-2024-results-and-provides-business-update.html
Why Trevena (TRVN) Stock Is Down 43% Today
October 8, 2024  |  msn.comhttps://www.msn.com/en-us/money/other/why-trevena-trvn-stock-is-down-43-today/ar-AA1rPZTc
Trevena, Inc. Faces Delisting from Nasdaq
October 6, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/trevena-inc-faces-delisting-from-nasdaq/ar-AA1rLb4Q

New MarketBeat Followers Over Time

Top Headlines

View All Headlines
Green upward arrow between two coin stacks on a desk, with a computer monitor showing financial charts in the background.
A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
By Nathan Reiff | July 22, 2026
Illustration of a PayPal vault opened to reveal a glowing PYUSD coin, with a Stripe and Advent International acquisition proposal folder nearby.
PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued?
By Jessica Mitacek | July 22, 2026
Gold Bitcoin tokens float around the Strategy logo, underscoring its renewed push to buy more digital assets.
Strategy's Structural Strength: Hidden in a $8 Billion Illusion
By Jeffrey Neal Johnson | August 2, 2026
Glass office towers with glowing digital network lines overlay, symbolizing tech industry data connectivity and market activity.
Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of Truth
By Bridget Bennett | August 7, 2026
Circle logo illuminated on a display screen in a dark room with glowing teal and purple light lines.
Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race
By Jeffrey Neal Johnson | July 30, 2026
Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Statera Biopharma stock logo

Statera Biopharma NASDAQ:STAB

$0.0002 0.00 (0.00%)
As of 08/10/2026 09:30 AM Eastern

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0001 0.00 (0.00%)
As of 08/10/2026 03:49 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.0010 0.00 (0.00%)
As of 08/7/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas